RUXOLITINIB PHOSPHATE - Generic Drug Details

What are the generic sources for ruxolitinib phosphate and what is the scope of freedom to operate?

Ruxolitinib phosphate is the generic ingredient in two branded drugs marketed by Incyte Corp and is included in two NDAs. There are twenty-two patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Ruxolitinib phosphate has three hundred and thirty-seven patent family members in forty-nine countries.

There are two drug master file entries for ruxolitinib phosphate. One supplier is listed for this compound.

Summary for RUXOLITINIB PHOSPHATE

International Patents:	337
US Patents:	22
Tradenames:	2
Applicants:	1
NDAs:	2
Drug Master File Entries:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	65
Clinical Trials:	27
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for RUXOLITINIB PHOSPHATE
DailyMed Link:	RUXOLITINIB PHOSPHATE at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for RUXOLITINIB PHOSPHATE

Constraining patent/regulatory exclusivity:

8,722,693*PED

Dosage:

TABLET;ORAL

Constraining patent/regulatory exclusivity:

8,722,693*PED

Dosage:

CREAM;TOPICAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for RUXOLITINIB PHOSPHATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
City of Hope Medical Center	Phase 2
Zhengzhou University	Phase 4
Philipps University Marburg Medical Center	Phase 2

See all RUXOLITINIB PHOSPHATE clinical trials

Pharmacology for RUXOLITINIB PHOSPHATE

Drug Class	Janus Kinase Inhibitor Kinase Inhibitor
Mechanism of Action	Janus Kinase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for RUXOLITINIB PHOSPHATE

D11AH	Agents for dermatitis, excluding corticosteroids
D11A	OTHER DERMATOLOGICAL PREPARATIONS
D11	OTHER DERMATOLOGICAL PREPARATIONS
D	Dermatologicals

L01EJ	Janus-associated kinase (JAK) inhibitors
L01E	PROTEIN KINASE INHIBITORS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

Paragraph IV (Patent) Challenges for RUXOLITINIB PHOSPHATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
OPZELURA	Cream	ruxolitinib phosphate	1.5%	215309	1	2023-07-31
JAKAFI	Tablets	ruxolitinib phosphate	5 mg, 10 mg, 15 mg, 20 mg, and 25 mg	202192	1	2015-12-17

US Patents and Regulatory Information for RUXOLITINIB PHOSPHATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Incyte Corp	JAKAFI	ruxolitinib phosphate	TABLET;ORAL	202192-002	Nov 16, 2011		RX	Yes	No
Incyte Corp	JAKAFI	ruxolitinib phosphate	TABLET;ORAL	202192-005	Nov 16, 2011		RX	Yes	Yes
Incyte Corp	OPZELURA	ruxolitinib phosphate	CREAM;TOPICAL	215309-001	Sep 21, 2021		RX	Yes	Yes	11,590,136

International Patents for RUXOLITINIB PHOSPHATE

Country	Patent Number	Title	Estimated Expiration
South Korea	101391900
Singapore	10201503983Q	Topical Formulation for a JAK Inhibitor
European Patent Office	3466953	DÉRIVÉ DE PYRROLO[2,3-B]PYRIMIDINE EN TANT QU'INHIBITEUR DE JANUS KINASE (PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE AS JANUS KINASE INHIBITOR)

Supplementary Protection Certificates for RUXOLITINIB PHOSPHATE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1966202	92137	Luxembourg		PRODUCT NAME: RUXOLITINIB, OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/12/773/001-003 20120828
2455382	LUC00016	Luxembourg		PRODUCT NAME: RUXOLITINIB, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/12/773/001-016 20150313
1966202	PA2013002	Lithuania

Market Dynamics and Financial Trajectory for Ruxolitinib Phosphate

Last updated: September 22, 2025

Introduction

Ruxolitinib Phosphate, marketed primarily as Jakafi (or Jakavi in some regions), stands as a pivotal therapeutic agent in the treatment of myeloproliferative neoplasms (MPNs), such as myelofibrosis and polycythemia vera. As a Janus kinase (JAK) 1 and 2 inhibitor, it has revolutionized management strategies for these conditions, with its unique mechanism of action addressing cytokine-driven pathological proliferation. This analysis explores the market dynamics influencing Ruxolitinib Phosphate's growth trajectory, alongside an assessment of its financial outlook amid competitive, regulatory, and technological factors.

---

Market Landscape and Epidemiological Drivers

The global MPN market is a key determinant in Ruxolitinib’s revenue profile. Myelofibrosis and polycythemia vera have a combined estimated prevalence of approximately 10-15 cases per 100,000 individuals, with the global patient population in the hundreds of thousands [1]. The adoption of Ruxolitinib as the standard of care for intermediate- and high-risk myelofibrosis has expanded, driven by its demonstrated efficacy in symptom management and spleen size reduction, as validated through pivotal clinical trials such as COMFORT-I and COMFORT-II [2].

India, China, and other emerging markets present increasing opportunities due to rising diagnosis rates and improving healthcare access. For instance, the aging global population further amplifies demand, as MPN prevalence correlates with advanced age. The ongoing rise in awareness and early diagnosis contributes positively to market size.

---

Competitive and Pharmacological Landscape

Ruxolitinib’s first-mover advantage positions it prominently; however, the competitive landscape is punctuated by efforts from biotech firms and pharmaceutical giants developing next-generation JAK inhibitors. Notably, Fedratinib (Inrebic) gained FDA approval for myelofibrosis in 2019, offering an alternative for patients intolerant or resistant to Ruxolitinib [3].

Additionally, emerging agents targeting different pathways—such as the CPI-0712 JAK2 inhibitor and combination therapies addressing MPL, CALR mutations—could influence Ruxolitinib’s market share. The competitive edge rests on drug efficacy, safety profiles, and ease of administration.

---

Regulatory and Pricing Considerations

Regulatory landscapes significantly regulate product access and market penetration. Ruxolitinib's initial approval was granted in multiple jurisdictions (FDA, EMA, etc.), facilitating rapid adoption. Price negotiations, reimbursement policies, and value-based pricing strategies underpin its financial success.

In major markets like the United States and European Union, Ruxolitinib commands premium pricing due to its clinical benefits. For instance, the typical annual cost exceeds $100,000 per patient [4], with affordability and insurance coverage influencing treatment uptake. Generic entry remains distant as of 2023, owing to patent Exclusivities, but imminent patent expirations could alter market dynamics within the next decade.

---

R&D and Pipeline Developments

Continued R&D investments target expanding Ruxolitinib’s indications, including graft-versus-host disease, alopecia areata, and potentially cardiovascular conditions. Notably, the expansion into combination regimens—for example, with PI3K inhibitors or epigenetic therapies—aims to enhance efficacy and manage resistance.

Current pipeline developments could thus bolster long-term revenues, especially if compounded therapies become standard. The exploration of JAK inhibitors in COVID-19 management signifies broader therapeutic relevance, potentially expanding Ruxolitinib's application landscape [5].

---

Market Challenges and Risks

While Ruxolitinib maintains clinical prominence, several challenges threaten its growth trajectory:

• Patent Expiry & Generic Competition: Increased risk of biosimilars or generics post-expiry could erode revenue streams.
• Pricing Pressures: Payers demand cost-effectiveness, potentially curbing pricing power.
• Safety & Tolerability: Risks such as anemia and thrombocytopenia necessitate careful patient management, with adverse events possibly limiting broad application.
• Regulatory Hurdles: Accelerated approvals for new indications demand substantial clinical evidence, entailing high R&D costs.

---

Financial Trajectory and Revenue Outlook

Johnson & Johnson, the exclusive marketer of Jakafi in the U.S., reported global sales exceeding $1.2 billion in 2022, a figure propelled by consistent demand and expanding indications [4]. Growth is projected to remain robust, driven by increased aging populations and ongoing clinical research.

Analysts estimate a compound annual growth rate (CAGR) of approximately 7-9% through 2028, contingent on successful pipeline progression and market expansion. Margins remain favorable owing to the drug’s premium pricing and high clinical value. Nonetheless, evolving patent protections and potential biosimilar competition could temper long-term growth, necessitating diversification in indications and potential combination therapies.

---

Geographical Dynamics

North America remains the largest market due to advanced healthcare infrastructure, high disease awareness, and favorable reimbursement frameworks. The European Union exhibits similar trends but faces pricing pressures. In emerging economies, market penetration is limited but growing, driven by expanding healthcare budgets and increasing disease burden.

---

Summary of Market Drivers

• Increasing prevalence of MPNs, particularly in aging populations
• Favorable clinical trial outcomes reinforcing treatment standards
• Regulatory approvals expanding indications
• High pricing power supported by clinical benefits
• R&D efforts targeting broader therapeutic applications

---

Conclusion

Ruxolitinib Phosphate's market trajectory exhibits steady growth fueled by its unique clinical efficacy, expanding indications, and strong patent protections. Although competitive pressures, pricing constraints, and patent expirations pose risks, ongoing pipeline developments and the rising global burden of MPNs suggest a resilient financial outlook over the medium term. Strategic partnerships, pipeline diversification, and market expansion into emerging economies will be critical for sustaining growth.

---

Key Takeaways

• Ruxolitinib remains a dominant JAK inhibitor for MPNs, with projected continued growth.
• Patent protections and pricing strategies are central to sustaining revenue streams.
• Competition from emerging JAK inhibitors could challenge market share.
• Expanding indications and combination therapies offer long-term revenue diversification.
• Emerging markets present opportunities but require tailored strategies for market entry.

---

FAQs

1. What are the primary indications for Ruxolitinib Phosphate?
   Ruxolitinib is primarily indicated for intermediate- and high-risk myelofibrosis, polycythemia vera refractory to hydroxyurea, and chronic graft-versus-host disease (cGVHD).

2. How does patent expiry impact Ruxolitinib’s market?
   Patent expiry could allow biosimilars or generic competitors to enter markets, potentially reducing prices and eroding exclusivity, which may impact revenue growth.

3. What are the major competitors to Ruxolitinib?
   Fedratinib (Inrebic) is FDA-approved as an alternative for myelofibrosis; other emerging JAK inhibitors and combination therapies also compete in this space.

4. How does pricing influence Ruxolitinib’s market access?
   High treatment costs necessitate favorable insurance reimbursement; pricing strategies significantly impact patient access and market penetration.

5. What are the future prospects for Ruxolitinib in new therapeutic areas?
   Ongoing clinical trials exploring its role in autoimmune diseases, graft-versus-host disease, and potentially COVID-19 suggest expanding therapeutic relevance and revenue avenues.

---

Sources:

[1] Global Myeloproliferative Neoplasms Market, Market Research Future, 2022.
[2] Pivotal Clinical Trials for Ruxolitinib, Leukemia & Lymphoma Society, 2021.
[3] FDA Approval of Fedratinib, U.S. Food & Drug Administration, 2019.
[4] Johnson & Johnson FY2022 Annual Report.
[5] Ruxolitinib in COVID-19, ClinicalTrials.gov, 2021.